ARNI as first-line therapy in de novo HFrEF patients after ADHF event - PACE-CME

ARNI as firstline therapy in de novo HFrEF patients after ADHF event

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Incident hyperkalemia, RAASi use and outcomes in acute hospitalized HF patients
Incident hyperkalemia, RAASi use and outcomes in acute hospitalized HF patients
ESC Heart Failure 2019
Incident hyperkalemia, RAASi use and outcomes in acute hospitalized HF patients
A novel parameter for proximal tubular function in HF
A novel parameter for proximal tubular function in HF
ESC Heart Failure 2019
A novel parameter for proximal tubular function in HF
Higher dose of loop diuretics limits uptitration RAASi in HFrEF
Higher dose of loop diuretics limits uptitration RAASi in HFrEF
ESC Heart Failure 2019
Higher dose of loop diuretics limits uptitration RAASi in HFrEF
Potassium binder results in more persistent use of spironolactone in resistant hypertension and CKD, also in a group of HF
Potassium binder results in more persistent use of spironolactone in resistant hypertension and CKD, also in a group of HF
ESC Heart Failure 2019
Potassium binder results in more persistent use of spironolactone in resistant hypertension and CKD, also in a group of HF